Dendritic Biomaterials for Oral Delivery of Chemotherapeutics

用于口服化疗药物的树突状生物材料

• 批准号: 7627049
• 负责人: Hamid Ghandehari
• 金额: $ 31.34万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-08-22 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7627049
• 关键词: Biocompatible Materials; Biological Availability; Biopolymers; Blood Circulation; Camptothecin Analogue; Characteristics; Charge; Chemistry; Colorectal Cancer; Data; Dendrimers; Drug Delivery Systems; Drug Transport; Drug toxicity; Drug usage; Environment; Enzymes; Epithelial; Epithelial Cells; Epithelium; Equilibrium; Exhibits; Hydrolysis; In Situ; In Vitro; Intestines; Label; Metastatic Neoplasm to the Liver; Modeling; Mucous Membrane; Mus; Nature; Oral; Pathway interactions; Permeability; Pharmaceutical Preparations; Polymers; Process; Research; Route; SN-38; Site; System; Testing; Therapeutic; Toxic effect; Water; absorption; base; cytotoxicity; design; gastrointestinal; improved; in vivo; intestinal epithelium; monolayer; novel; prototype; size; small molecule; targeted delivery

DESCRIPTION (provided by applicant): Targeted delivery of drugs using water-soluble polymeric carriers improves efficacy and reduces toxicity. However, the large size of most biopolymers necessitates administration via the parenteral route. As oral absorption remains the preferred route of administration, many pharmacologically active drugs as well as polymers have poor systemic availability when administered orally. Our preliminary data indicate that poly(amidoamine) (PAMAM) dendrimers efficiently translocate across epithelial cell monolayers and can effectively increase the transfer of small molecules. Thus, this polymeric carrier may be used to improve the oral absorption of therapeutic molecules into the systemic circulation and direct them to the target sites via the creation of a conjugate delivery system. In the current proposal we aim to evaluate the influence of structural features of PAMAM dendrimers on their transepithelial transport and capitalize on both their permeation enhancing effects to increase the oral bioavailability and their macromolecular nature to facilitate targeting of a model drug. The long-term objective of this proposal is to develop polymeric systems based on PAMAM dendrimers for targeted oral drug delivery. The central hypothesis to our proposed research is that the permeation and targeting potential of poorly absorbable drugs is enhanced by conjugation to PAMAM dendrimers. To test our hypothesis, we will study the following Specific Aims: 1) To evaluate the influence of charge and drug loading on intestinal transport and cytotoxicity of PAMAM dendrimers. 2) To evaluate the in vitro stability and in situ bioavailability of dendrimer-drug conjugates. 3) To evaluate the in vivo bioavailability, antitumor efficacy and toxicity of the conjugates in a murine model of liver metastasis of colorectal cancer. 4) To delineate the intestinal transport mechanism(s) of PAMAM dendrimers. By evaluating the influence of structural features on permeability and stability we expect to find prototype PAMAM dendrimers that can increase oral availability of SN38, exhibit minimal toxicity, and target the drug effectively to liver metastases. Delineation of the mechanism(s) of transport will aid in the rationale design of novel polymeric carriers for oral delivery. In the long term this may allow for the delivery of a variety of therapeutic molecules in a more controlled and targeted manner across the Gl tract using tailor-made PAMAM dendrimers as polymeric carriers.

描述（由申请人提供）：使用水溶性聚合物载体靶向递送药物可提高功效并降低毒性。但是，大多数生物聚合物的大尺寸都需要通过肠胃外途径进行给药。由于口服吸收仍然是首选的给药途径，因此许多药理活性药物以及聚合物在口服时的全身可用性较差。我们的初步数据表明，聚（Amidoamine）（PAMAM）树枝状聚合物有效地转移到上皮细胞单层中，并可以有效地增加小分子的转移。因此，该聚合物载体可用于改善治疗分子的口服吸收到系统性循环中，并通过创建共轭递送系统将其引导到目标位点。在当前的提案中，我们旨在评估PAMAM树突聚合物对其跨月型运输的结构特征的影响，并利用它们的渗透增强作用，以增强口服生物利用度及其大分子性质，以促进模型药物的靶向。该提案的长期目标是开发基于PAMAM树枝状聚合物的聚合物系统，用于靶向口服药物。我们提出的研究的中心假设是，通过与PAMAM树状聚合物的结合，可以增强吸收不良药物的渗透和靶向潜力。为了检验我们的假设，我们将研究以下具体目的：1）评估电荷和药物负荷对PAMAM树突聚合物的肠道运输和细胞毒性的影响。 2）评估树枝状聚合物 - 药物结合物的体外稳定性和原位生物利用度。 3）评估结合物的体内生物利用度，抗肿瘤功效和结合物的毒性在结直肠癌的肝转移模型中。 4）描述PAMAM树状聚合物的肠运输机制。通过评估结构特征对渗透性和稳定性的影响，我们期望找到可以增加口服SN38的原型PAMAM树枝状聚合物，表现出最小的毒性，并有效地将药物靶向肝转移。运输机制的描述将有助于新型聚合物载体的理由设计进行口服递送。从长远来看，这可以允许使用裁缝制造的PAMAM树状聚合物作为聚合物载体，以更具控制和靶向的方式在整个GL道上以更具控制和靶向的方式递送各种治疗分子。